AtriCure, Inc. Stock price

Equities

ATRC

US04963C2098

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 04:00:00 2024-02-23 pm EST 5-day change 1st Jan Change
33.56 USD -1.29% Intraday chart for AtriCure, Inc. +2.57% -5.97%
Sales 2024 * 461M Sales 2025 * 526M Capitalization 1.6B
Net income 2024 * -34M Net income 2025 * -27M EV / Sales 2024 * 3.34 x
Net cash position 2024 * 58.07M Net cash position 2025 * 73.18M EV / Sales 2025 * 2.9 x
P/E ratio 2024 *
-45.7 x
P/E ratio 2025 *
-58.4 x
Employees 1,200
Yield 2024 *
-
Yield 2025 *
-
Free-Float 97.02%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.29%
1 week+2.57%
Current month-1.47%
1 month-0.06%
3 months-20.25%
6 months-26.34%
Current year-5.97%
More quotes
1 week
32.16
Extreme 32.16
34.51
1 month
29.68
Extreme 29.675
35.84
Current year
29.68
Extreme 29.675
36.34
1 year
29.68
Extreme 29.675
59.61
3 years
29.68
Extreme 29.675
89.18
5 years
22.57
Extreme 22.57
89.18
10 years
13.19
Extreme 13.185
89.18
More quotes
Managers TitleAgeSince
Chief Executive Officer 53 12-11-01
Director of Finance/CFO 46 14-06-30
Chief Tech/Sci/R&D Officer 52 17-02-28
Members of the board TitleAgeSince
Director/Board Member 60 19-12-03
Chief Executive Officer 53 12-11-01
Director/Board Member 73 16-11-09
More insiders
Date Price Change Volume
24-02-23 33.56 -1.29% 418,285
24-02-22 34 +2.94% 511,547
24-02-21 33.03 +0.06% 379,418
24-02-20 33.01 +0.89% 639,438
24-02-16 32.72 -4.36% 1,650,228

Delayed Quote Nasdaq, February 23, 2024 at 04:00 pm EST

More quotes
AtriCure, Inc. provides technologies for the treatment of atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain. The Company develops, manufactures and sells devices designed primarily for the surgical ablation of cardiac tissue, systems designed for the exclusion of the LAA and devices designed to block pain by temporarily ablating peripheral nerves. These devices are developed and marketed to medical centers. Its ablation and left atrial appendage (LAA) management products are used by physicians during both open-heart and minimally invasive procedures. Its products for open and minimally invasive ablation include Isolator Synergy Clamps and Multifunctional Pens and Linear Ablation Devices. Its products for open ablation include cryoICE Cryoablation System. Its products for minimally invasive ablation include EPi-Sense Guided Coagulation System with VisiTrax Technology. Its appendage management products include AtriClip System.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
33.56 USD
Average target price
54.38 USD
Spread / Average Target
+62.02%
Consensus
  1. Stock
  2. Equities
  3. Stock AtriCure, Inc. - Nasdaq
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer